Deerfield Management Company, L.P. (Series C) Cabaletta Bio, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$7.22 - $18.82 $5.74 Million - $15 Million	-794,398 Reduced 63.12%	464,252 $3.47 Million
Q1 2024 May 15, 2024	SELL	$16.79 - $25.38 $12.6 Million - $19 Million	-749,079 Reduced 37.31%	1,258,650 $21.5 Million
Q4 2023 Feb 14, 2024	SELL	$12.21 - $23.36 $4.06 Million - $7.76 Million	-332,389 Reduced 14.2%	2,007,729 $45.6 Million
Q2 2023 Aug 14, 2023	BUY	$7.65 - $13.95 $14.4 Million - $26.2 Million	1,875,866 Added 404.06%	2,340,118 $30.2 Million
Q2 2020 Aug 14, 2020	SELL	$6.39 - $11.28 $5.24 Million - $9.25 Million	-820,061 Reduced 63.85%	464,252 $5.17 Million
Q1 2020 May 15, 2020	SELL	$6.0 - $18.67 $2.07 Million - $6.43 Million	-344,191 Reduced 21.14%	1,284,313 $9.38 Million
Q4 2019 Feb 14, 2020	BUY	$7.88 - $17.71 $12.8 Million - $28.8 Million	1,628,504 New	1,628,504 $22.8 Million

Others Institutions Holding CABA

# of Institutions

126

Shares Held

47.9M

Call Options Held

202K

Put Options Held

110K

Jennison Associates LLC

5.63M
Shares

$12.9 Million
0.02% of portfolio
Black Rock Inc. New York, NY

4.76M
Shares

$10.9 Million
0.0% of portfolio
Fred Alger Management, LLC New York, NY

4.12M
Shares

$9.43 Million
0.1% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

3.67M
Shares

$8.41 Million
0.01% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

3.04M
Shares

$6.95 Million
0.03% of portfolio

View Full List

About Cabaletta Bio, Inc.

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $66.4M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

More about CABA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account